- Home
- WOOF vs SANA Comparison
WOOF vs SANA Comparison
Compare WOOF & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOOF
- SANA
- Stock Information
- Founded
- WOOF 1965
- SANA 2018
- Country
- WOOF United States
- SANA United States
- Employees
- WOOF N/A
- SANA N/A
- Industry
- WOOF Other Specialty Stores
- SANA Medicinal Chemicals and Botanical Products
- Sector
- WOOF Consumer Discretionary
- SANA Health Care
- Exchange
- WOOF Nasdaq
- SANA Nasdaq
- Market Cap
- WOOF 986.5M
- SANA 983.4M
- IPO Year
- WOOF 2021
- SANA 2021
- Fundamental
- Price
- WOOF $3.55
- SANA $4.45
- Analyst Decision
- WOOF Hold
- SANA Strong Buy
- Analyst Count
- WOOF 11
- SANA 6
- Target Price
- WOOF $3.91
- SANA $8.00
- AVG Volume (30 Days)
- WOOF 2.2M
- SANA 3.8M
- Earning Date
- WOOF 12-04-2025
- SANA 11-07-2025
- Dividend Yield
- WOOF N/A
- SANA N/A
- EPS Growth
- WOOF N/A
- SANA N/A
- EPS
- WOOF N/A
- SANA N/A
- Revenue
- WOOF $6,045,495,000.00
- SANA N/A
- Revenue This Year
- WOOF N/A
- SANA N/A
- Revenue Next Year
- WOOF $1.16
- SANA N/A
- P/E Ratio
- WOOF N/A
- SANA N/A
- Revenue Growth
- WOOF N/A
- SANA N/A
- 52 Week Low
- WOOF $2.28
- SANA $1.26
- 52 Week High
- WOOF $6.29
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- WOOF 47.36
- SANA 69.58
- Support Level
- WOOF $3.62
- SANA $4.10
- Resistance Level
- WOOF $3.88
- SANA $4.82
- Average True Range (ATR)
- WOOF 0.18
- SANA 0.29
- MACD
- WOOF -0.03
- SANA 0.08
- Stochastic Oscillator
- WOOF 35.07
- SANA 80.19
About WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.